|
|
||||||||
Division of Radiopharmaceutical Chemistry, Division of Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Correspondence: For reprints contact: Tatsuo Ido, PhD, Div. of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Aramaki-aza-aoba, Sendai, Miyagi, 980, Japan.
ABSTRACT
The in vivo D2-receptor specific brain uptake of N-[(2RS,3RS)-1-benzyl-2-methyl-3-pyrrolidinyl] -5-chloro-2-methoxy-4-[11C]methylaminobenzamide([11C]YM-09151-2), was investigated. In rat brain the high uptake of [11C]YM-09151-2 in striatum was displaced with sulpiride, spiroperidol, and YM-09151-2. SCH-23390 and ritanserin, D1-dopamine and S2-serotonin antagonists, showed no effect on the distribution of [11C]YM-09151-2. In the striatum at 60 min, 95% of the radioactivity was detected as [11C]YM-09151-2 by high performance liquid chromatography. On the other hand, 41% of 11C in the plasma at 60 min was observed as metabolites. In vivo autoradiography showed a high uptake of [11C]YM-09151-2 in the striatum and in the nucleus accumbens of rat brain. A high uptake of radioactivity was also found in the canine basal ganglia with positron emission tomography. The uptake was reduced by pretreatment with spiropendol. The present results demonstrate that [11C]YM-09151-2 is a D2 receptor specific compound and is a potential in vivo tracer for measuring D2 receptors.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |